We’re proud to announce the launch of the new corporate and product brands we’ve developed for US healthcare startup Evolution Biologyx.
The new brand centres around a disruptive positioning and a bold, standout identity, giving the business the powerful presence it needs to take on the more established, global brands in the regenerative therapeutics industry. It is part of a wider communications program we’ve been engaged with since the start of 2021.
Affinity New York’s COO, Chris O’Rourke, commented on the project:
"The regenerative therapeutics market is characterized by a number of generic brands that don’t provide much in the way of engagement and inspiration. We’ve worked in close partnership with the founding team to break that mould.
The new brand is distinct, contemporary and reflects the disruptive ambition of the business. Early indications from the Sales team suggest that it’s already driving growth."
The project involved a combined team from Affinity’s US and UK offices working closely with Evolution Biologyx’s founders and marketing team.
For more information on the project and a visual snapshot of the new brand, please see our Evolution Biologyx case study.